In addition, our work shows that targeting the TRIB3–EGFR interaction to promote EGFR degradation is a potential therapeutic option for the treatment of EGFR-related NSCLC cases (Fig. 8n). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.